Overcome Biochemical Aspirin Resistance Through Cilostazol Combination (ARCC)

Asan Medical Center

Status and phase: Completed; Phase 4

Conditions: Cerebral Infarction

Treatments: Drug: Cilostazol; Drug: placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00446641

ARCC

Details and patient eligibility

About

This study will recruit 316 ischemic stroke patients taking aspirin.

They will be randomly assigned into cilostazol group or placebo group. Every patients will take 200mg of cilostazol a day or placebo for 1 month.

The primary outcome variable of this study is rate of biochemical aspirin resistance on the Ultra Rapid Platelet Function Assay-ASA.

Full description

[Goal] To reveal the effect and safety of additional cilostazol for overcoming biochemical aspirin resistance.

[Trial Design] Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial

[Participants] Ischemic stroke patients taking aspirin

[Methods]

• Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial
• Investigational product: Cilostazol 200mg (100mg twice per day)
• Concomitant medication: Aspirin 100 mg per day
• Medication Duration: 1 month

[Outcome Variables]

Primary Outcome Variable:

• the proportion of patients with aspirin reaction units (ARUs) values ≥550 on the Ultra Rapid Platelet Function Assay-ASA

Secondary outcome variables:

• the proportion of patients with ARUs values ≥500 on the Ultra Rapid Platelet Function Assay-ASA
• ARUs values
• Bleeding time (BT)
• Fatal or major bleeding complications
• Any bleeding complications

Enrollment: 244 patients

Sex: All

Ages: 35+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Symptomatic cerebral infarction documented on MRI or CT
• More than 35 years of age
• Patients taking aspirin 100mg a day for 2 weeks or more before randomization

Exclusion criteria

• Patients taking any antiplatelets other than aspirin within 2 weeks before randomization
• Patients taking any anticoagulants within 2 weeks before randomization
• Patients taking thrombolytic therapy within 2 weeks before randomization
• Patients taking any NSAIDs within 2 weeks before randomization
• Patients who need to take NSAIDs regularly (e.g. rheumatic arthritis).
• Bleeding diathesis
• Chronic liver disease (ALT > 100 or AST > 100) or chronic renal disease (creatinine > 3.0mg/dl)
• Anemia (hemoglobin < 10mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3)
• Pregnant or lactating patients
• Patients scheduled for angioplasty or revascularization procedures within 4 weeks
• Patients scheduled for any surgery or invasive procedures within 4 weeks
• Patients having acute coronary syndrome

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

244 participants in 2 patient groups, including a placebo group

1 Cilostazol

Experimental group

Description:

100mg of Cilostazol twice a day

Treatment:

Drug: Cilostazol

Placebo

Placebo Comparator group

Description:

matching placebo to cilostazol

Treatment:

Drug: placebo